Concepedia
Statistics
Publications
9
Citations
1.5K
H-Index
Active since
2011
Affiliations
Clinica Universidad de Navarra(Current)
Instituto de Investigación Biomédica de Salamanca
Centro de Investigación del Cáncer
Navarre Institute of Health Research
Universidad de Salamanca
Sara Rodríguez is an author at Clinica Universidad de Navarra specializing in oncology, multiple myeloma, and medicine.
Publications per year
2011–2023
Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
Ranjana H. Advani, Joseph J. Buggy, Jeff P. Sharman et al. · Journal of Clinical Oncology · 2012 · 1.1K citations · Full text
Medicine, Oncology, Pharmacology +17
Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma
Ibai Goicoechea, Noemí Puig, María‐Teresa Cedena et al. · Blood · 2020 · 133 citations · Full text
Medicine, Cancer Biology, Oncology +17
Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma
Rosalinda Termini, David Žihala, Evangelos Terpos et al. · Clinical Cancer Research · 2022 · 52 citations · Full text
Medicine, Hematology, Oncology +17
Circulating tumor cells for comprehensive and multiregional non-invasive genetic characterization of multiple myeloma
Juan‐José Garcés, Gabriel Bretones, Leire Burgos et al. · Leukemia · 2020 · 47 citations · Full text
Medicine, Cancer Biology, Oncology +16
The Bruton's Tyrosine Kinase Inhibitor PCI-32765 Is Highly Active As Single-Agent Therapy in Previously-Treated Mantle Cell Lymphoma (MCL): Preliminary Results of a Phase II Trial
Lühua Wang, Peter Martin, Kristie A. Blum et al. · Blood · 2011 · 41 citations
Medicine, Hematology, Oncology +16
1–5 of 9